Tags

Type your tag names separated by a space and hit enter

Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Int J Antimicrob Agents. 2008 Jul; 32(1):55-61.IJ

Abstract

A new poly-aggregated form of amphotericin B was formulated as a non-microencapsulated form (P-AMB) or incorporated in albumin microspheres (MP-AMB) and compared with the conventional amphotericin B formulation (D-AMB). Mice were infected with Candida albicans and treated with two different intermittent dose regimens of the different amphotericin B formulations. Efficacy and toxicity were studied by the determination of survival rate, kidney colony-forming units counts, biochemical parameters and amphotericin B concentrations in plasma and organs. All the treatments significantly (P<0.05) increased the survival rate in relation to the untreated group, although non-statistically significant differences (P>0.05) were found between formulations and dosing regimens. All the treatments produced kidney toxicity, expressed by high urea levels. Kidney toxicity was especially significant for mice treated with the D-AMB formulation where unilateral kidney atrophy was observed in most of the mice, whereas most of the mice treated with P-AMB conserved both kidneys with a normal size and appearance. At 45 days post infection, variable distribution of amphotericin B in the body was obtained depending on the amphotericin B formulation. In conclusion, non-daily dosing regimens of P-AMB, which is less toxic than D-AMB, could be used as an alternative to the conventional D-AMB formulation to treat experimental candidiasis.

Authors+Show Affiliations

Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18534826

Citation

Espada, Raquel, et al. "Efficacy of Alternative Dosing Regimens of Poly-aggregated Amphotericin B." International Journal of Antimicrobial Agents, vol. 32, no. 1, 2008, pp. 55-61.
Espada R, Valdespina S, Molero G, et al. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Int J Antimicrob Agents. 2008;32(1):55-61.
Espada, R., Valdespina, S., Molero, G., Dea, M. A., Ballesteros, M. P., & Torrado, J. J. (2008). Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. International Journal of Antimicrobial Agents, 32(1), 55-61. https://doi.org/10.1016/j.ijantimicag.2008.02.025
Espada R, et al. Efficacy of Alternative Dosing Regimens of Poly-aggregated Amphotericin B. Int J Antimicrob Agents. 2008;32(1):55-61. PubMed PMID: 18534826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. AU - Espada,Raquel, AU - Valdespina,Suriñe, AU - Molero,Gloria, AU - Dea,María A, AU - Ballesteros,María P, AU - Torrado,Juan J, Y1 - 2008/06/04/ PY - 2007/11/28/received PY - 2008/02/28/revised PY - 2008/02/28/accepted PY - 2008/6/7/pubmed PY - 2008/9/13/medline PY - 2008/6/7/entrez SP - 55 EP - 61 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 32 IS - 1 N2 - A new poly-aggregated form of amphotericin B was formulated as a non-microencapsulated form (P-AMB) or incorporated in albumin microspheres (MP-AMB) and compared with the conventional amphotericin B formulation (D-AMB). Mice were infected with Candida albicans and treated with two different intermittent dose regimens of the different amphotericin B formulations. Efficacy and toxicity were studied by the determination of survival rate, kidney colony-forming units counts, biochemical parameters and amphotericin B concentrations in plasma and organs. All the treatments significantly (P<0.05) increased the survival rate in relation to the untreated group, although non-statistically significant differences (P>0.05) were found between formulations and dosing regimens. All the treatments produced kidney toxicity, expressed by high urea levels. Kidney toxicity was especially significant for mice treated with the D-AMB formulation where unilateral kidney atrophy was observed in most of the mice, whereas most of the mice treated with P-AMB conserved both kidneys with a normal size and appearance. At 45 days post infection, variable distribution of amphotericin B in the body was obtained depending on the amphotericin B formulation. In conclusion, non-daily dosing regimens of P-AMB, which is less toxic than D-AMB, could be used as an alternative to the conventional D-AMB formulation to treat experimental candidiasis. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/18534826/Efficacy_of_alternative_dosing_regimens_of_poly_aggregated_amphotericin_B_ DB - PRIME DP - Unbound Medicine ER -